125 related articles for article (PubMed ID: 8558515)
1. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.
Thomas BF; Adams IB; Mascarella SW; Martin BR; Razdan RK
J Med Chem; 1996 Jan; 39(2):471-9. PubMed ID: 8558515
[TBL] [Abstract][Full Text] [Related]
2. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis.
Tong W; Collantes ER; Welsh WJ; Berglund BA; Howlett AC
J Med Chem; 1998 Oct; 41(22):4207-15. PubMed ID: 9784095
[TBL] [Abstract][Full Text] [Related]
3. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Järbe TU; Lamb RJ; Lin S; Makriyannis A
Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent THC/anandamide (hybrid) analogs.
Bourne C; Roy S; Wiley JL; Martin BR; Thomas BF; Mahadevan A; Razdan RK
Bioorg Med Chem; 2007 Dec; 15(24):7850-64. PubMed ID: 17827022
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
6. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
Fride E; Barg J; Levy R; Saya D; Heldman E; Mechoulam R; Vogel Z
J Pharmacol Exp Ther; 1995 Feb; 272(2):699-707. PubMed ID: 7853184
[TBL] [Abstract][Full Text] [Related]
7. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
[TBL] [Abstract][Full Text] [Related]
8. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
Ryan WJ; Banner WK; Wiley JL; Martin BR; Razdan RK
J Med Chem; 1997 Oct; 40(22):3617-25. PubMed ID: 9357528
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of the phenolic hydroxyl in cannabinoid activity.
Reggio PH; Seltzman HH; Compton DR; Prescott WR; Martin BR
Mol Pharmacol; 1990 Dec; 38(6):854-62. PubMed ID: 2174506
[TBL] [Abstract][Full Text] [Related]
10. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories.
Barnett-Norris J; Guarnieri F; Hurst DP; Reggio PH
J Med Chem; 1998 Nov; 41(24):4861-72. PubMed ID: 9822555
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1992 Jan; 260(1):201-9. PubMed ID: 1309872
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.
Wiley JL; Golden KM; Ryan WJ; Balster RL; Razdan RK; Martin BR
Pharmacol Biochem Behav; 1997 Dec; 58(4):1139-43. PubMed ID: 9408225
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
Seltzman HH; Fleming DN; Thomas BF; Gilliam AF; McCallion DS; Pertwee RG; Compton DR; Martin BR
J Med Chem; 1997 Oct; 40(22):3626-34. PubMed ID: 9357529
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.
Adams IB; Ryan W; Singer M; Thomas BF; Compton DR; Razdan RK; Martin BR
J Pharmacol Exp Ther; 1995 Jun; 273(3):1172-81. PubMed ID: 7791088
[TBL] [Abstract][Full Text] [Related]
17. Assessment of structural commonality between tetrahydrocannabinol and anandamide.
Martin BR; Jefferson RG; Winckler R; Wiley JL; Thomas BF; Crocker PJ; Williams W; Razdan RK
Eur J Pharmacol; 2002 Jan; 435(1):35-42. PubMed ID: 11790376
[TBL] [Abstract][Full Text] [Related]
18. Preferred conformations of endogenous cannabinoid ligand anandamide.
Chen JZ; Han XW; Xie XQ
Life Sci; 2005 Mar; 76(18):2053-69. PubMed ID: 15826873
[TBL] [Abstract][Full Text] [Related]
19. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
Brizzi A; Brizzi V; Cascio MG; Corelli F; Guida F; Ligresti A; Maione S; Martinelli A; Pasquini S; Tuccinardi T; Di Marzo V
J Med Chem; 2009 Apr; 52(8):2506-14. PubMed ID: 19331413
[TBL] [Abstract][Full Text] [Related]
20. Cannabis: discrimination of "internal bliss"?
Wiley JL
Pharmacol Biochem Behav; 1999 Oct; 64(2):257-60. PubMed ID: 10515300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
